Skip to main contentSkip to navigationSkip to search

Press release

Camurus Annual Report for 2020

14 April 2021 | Regulatory

Lund, Sweden — 14 April 2021 — Camurus (CAMX) today announces that the Annual Report for 2020 now is available at the company’s website:

For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92

Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37

About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit

This information is information that Camurus AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 3:00pm CET on 14 April 2021.

TypeError: Cannot read properties of undefined (reading 'url')